Results 171 to 180 of about 96,185 (308)

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

Allergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk, J. J. Otten, H. B. E. Elzinga, R. J. L. van der Lans, G. F. J. P. Adriaensen, L. B. L. Benoist, D. R. Hoven, W. J. Fokkens, S. Reitsma, PolyREG Consortium, A.B. Rinia, I. Krebbers, I.J. Kleiss, M. E. Cornet   +13 more
wiley   +1 more source

Intranasal drug delivery: Unlocking the nose-to-brain route for central nervous system therapies. [PDF]

Int J Pharm X
Alwali B, Parumasivam T, Al-Tabakha MM.
europepmc   +1 more source

Intranasal Administration of Mammary Tumour Milk Factor [PDF]

British Journal of Cancer, 1949
openaire   +2 more sources

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

Allergy, EarlyView.
The RHAPSODY multinational study investigated 26 months of continuous treatment with 5‐grass‐pollen sublingual SLIT drops in adults with moderate‐to‐severe grass‐pollen‐induced allergic rhinoconjunctivitis. The primary efficacy endpoint (the average daily total combined score) showed statistically significant differences in favour of the active ...
Alain Didier, Ruta Gronskyte Juhl, Terrie Dalgaard, Antoine Chartier, Philippe Devillier   +4 more
wiley   +1 more source

Reversal, Risk, and Responsibility in the Era of Potent Opioids and Overdose. [PDF]

Anesthesiology
Rathmell JP, Kern SE.
europepmc   +1 more source

Interstitial granulomatous drug reaction after intranasal desmopressin administration

Indian Journal of Dermatology, 2016
Maione, Vincenzo, STINCO, Giuseppe, Orsaria, Maria, Errichetti, Ezio   +3 more
openaire   +2 more sources

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

Allergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm, Mohammed Zghaebi, Bita Hambrecht, Tanja Kalic, Christopher C. Udoye, Rudolf Manz, Barbara Bohle, Katarzyna M. Sitnik, Julia Eckl‐Dorna, Heimo Breiteneder   +9 more
wiley   +1 more source

Intranasal Diazepam Outperforms Midazolam and Lorazepam in Early Seizure Control in Pilocarpine-Induced Mice Model. [PDF]

Neurochem Res
Tong AH, Zhao J, Li J, Ban W, Wang RJ, Xie Y, Zhang Y, Zuo Z.   +7 more
europepmc   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source

Intranasal Drug Delivery in Neuropharmacology: Advances in Brain-Targeted Therapies and Bioethical Challenges. [PDF]

Biomedicines
Damian SI, David SM, Nour M, Halitchi GL, Ciurlea SA, Stefanache A, Duma OO, Calin G, Spaiuc D.   +8 more
europepmc   +1 more source